Jump Financial, LLC Vaxcyte, Inc. Transaction History

Jump Financial, LLC

$8.87 Billion
Q3 2025

A detailed history of Jump Financial, LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Jump Financial, LLC holds 191,700 shares of PCVX stock, worth $9.27 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

191,700

Previous 403,597 52.5%

Holding current value

$9.27 Million

Previous $13.1 Million 47.37%

% of portfolio

0.08%

Previous 0.17%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$29.67 - $37.37 $6.29 Million - $7.92 Million	-211,897 Reduced 52.5%	191,700 $6.91 Million
Q2 2025 Aug 13, 2025	BUY	$28.04 - $37.2 $8.51 Million - $11.3 Million	303,497 Added 303.19%	403,597 $13.1 Million
Q1 2025 May 14, 2025	BUY	$37.76 - $92.13 $3.78 Million - $9.22 Million	100,100 New	100,100 $3.78 Million
Q3 2024 Nov 14, 2024	BUY	$70.52 - $117.12 $3.63 Million - $6.03 Million	51,516 New	51,516 $5.88 Million
Q1 2024 May 13, 2024	BUY	$59.79 - $81.05 $1.81 Million - $2.45 Million	30,224 New	30,224 $2.06 Million

Q1 2023 Oct 21, 2024	BUY	$36.27 - $47.2 $3.84 Million - $4.99 Million	105,800 New	105,800 $3.97 Million
Q1 2023 May 03, 2023	BUY	$36.27 - $47.2 $1.96 Million - $2.56 Million	54,158 Added 104.87%	105,800 $3.97 Million
Q4 2022 Feb 13, 2023	BUY	$20.58 - $47.95 $1.06 Million - $2.48 Million	51,642 New	51,642 $2.48 Million
Q1 2021 May 17, 2021	SELL	$18.66 - $29.16 $151,146 - $236,196	-8,100 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$26.57 - $51.74 $215,217 - $419,094	8,100 New	8,100 $215,000

Others Institutions Holding PCVX

# of Institutions

319

Shares Held

133M

Call Options Held

408K

Put Options Held

116K

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $2.87B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jump Financial, LLC with notifications on news.

Account

Jump Financial, LLC Vaxcyte, Inc. Transaction History